PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15806111-1	2005	1 To clarify the mechanism of mast cell TNF secretion, especially its release process after being produced, we utilized an antiallergic drug, azelastine (4-(p-chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)- phthalazinone), which has been reported to inhibit TNF release without affecting its production in ionomycin-stimulated RBL-2H3 cells.	azelastine	142-152	tumor necrosis factor	Rattus norvegicus	40-43	
15806111-9	2005	6 These results suggest that (alpha)PKC mediates the TNF release process and azelastine inhibits TNF release by selectively interfering with the recruitment of (alpha)PKC in the pathway activated by ionomycin in RBL-2H3 cells.	azelastine	77-87	tumor necrosis factor	Rattus norvegicus	97-100	
15806111-1	2005	1 To clarify the mechanism of mast cell TNF secretion, especially its release process after being produced, we utilized an antiallergic drug, azelastine (4-(p-chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)- phthalazinone), which has been reported to inhibit TNF release without affecting its production in ionomycin-stimulated RBL-2H3 cells.	azelastine	142-152	tumor necrosis factor	Rattus norvegicus	270-273	
15806111-1	2005	1 To clarify the mechanism of mast cell TNF secretion, especially its release process after being produced, we utilized an antiallergic drug, azelastine (4-(p-chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)- phthalazinone), which has been reported to inhibit TNF release without affecting its production in ionomycin-stimulated RBL-2H3 cells.	azelastine	154-232	tumor necrosis factor	Rattus norvegicus	40-43	
15806111-1	2005	1 To clarify the mechanism of mast cell TNF secretion, especially its release process after being produced, we utilized an antiallergic drug, azelastine (4-(p-chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)- phthalazinone), which has been reported to inhibit TNF release without affecting its production in ionomycin-stimulated RBL-2H3 cells.	azelastine	154-232	tumor necrosis factor	Rattus norvegicus	270-273	
9300717-0	1997	Suppression of TNF-alpha secretion by azelastine in a rat mast (RBL-2H3) cell line: evidence for differential regulation of TNF-alpha release, transcription, and degranulation.	azelastine	38-48	tumor necrosis factor	Rattus norvegicus	15-24	
9585152-5	1998	Azelastine inhibited TNF-alpha release at concentrations lower than those needed for the inhibition of degranulation.	azelastine	0-10	tumor necrosis factor	Rattus norvegicus	21-30	
9585152-6	1998	In antigen-stimulated cells, azelastine also inhibited equipotently TNF-alpha mRNA expression/protein synthesis, TNF-alpha release and Ca2+ influx.	azelastine	29-39	tumor necrosis factor	Rattus norvegicus	68-77	
9585152-6	1998	In antigen-stimulated cells, azelastine also inhibited equipotently TNF-alpha mRNA expression/protein synthesis, TNF-alpha release and Ca2+ influx.	azelastine	29-39	tumor necrosis factor	Rattus norvegicus	113-122	
9585152-7	1998	In ionomycin-stimulated cells, however, azelastine inhibited TNF-alpha release to a greater extent than TNF-alpha mRNA expression/protein synthesis and Ca2+ influx, indicating that azelastine inhibits the release process more potently than transcription or production of TNF-alpha by interfering with a signal other than Ca2+.	azelastine	40-50	tumor necrosis factor	Rattus norvegicus	61-70	
9585152-4	1998	We compared the effects of azelastine, an anti-allergic drug, on TNF-alpha secretion, on Ca2+ signal, and on degranulation in an antigen- or ionomycin-stimulated rat mast RBL-2H3 cell line.	azelastine	27-37	tumor necrosis factor	Rattus norvegicus	65-74	
9300717-4	1997	In a rat mast RBL-2H3 cell line, azelastine inhibited Ag- and ionomycin-induced TNF-alpha release with IC50 values of 25.7 +/- 3.4 microM and 1.66 +/- 0.45 microM, respectively.	azelastine	33-43	tumor necrosis factor	Rattus norvegicus	80-89	
9300717-6	1997	In Ag-stimulated cells, azelastine also inhibited TNF-alpha mRNA expression, TNF-alpha protein synthesis and release, and, possibly related to these effects, Ca2+ influx.	azelastine	24-34	tumor necrosis factor	Rattus norvegicus	50-59	
9300717-6	1997	In Ag-stimulated cells, azelastine also inhibited TNF-alpha mRNA expression, TNF-alpha protein synthesis and release, and, possibly related to these effects, Ca2+ influx.	azelastine	24-34	tumor necrosis factor	Rattus norvegicus	77-86	
9300717-7	1997	In ionomycin-stimulated cells, however, azelastine inhibited TNF-alpha release to a greater extent than mRNA expression/protein synthesis and Ca2+ influx, suggesting that azelastine inhibits the release process more potently than transcription or production of TNF-alpha by interfering with a signal other than Ca2+.	azelastine	40-50	tumor necrosis factor	Rattus norvegicus	61-70	
9300717-8	1997	Azelastine added 1 h after ionomycin stimulation also immediately blocked subsequent release of TNF-alpha, which had been produced in the cells, without affecting Ca2+ influx.	azelastine	0-10	tumor necrosis factor	Rattus norvegicus	96-105